Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants.

International journal of molecular sciences - 2 Apr 2026

Mostaq Md Saqline, Amin Mohammad N, Raphael Amanda, Asbury Celine, Gupta Anish, Gu Xin, Han Xianlin, Sekulic Davorka, Michalak Pawel, Kang Lin, Liu Yong-Yu

Abstract excerpt

Glucosylceramide synthase (GCS) catalyzes ceramide glycosylation in response to cell stress that produces glucosylceramide and other glycosphingolipids. GCS overexpression is a cause of drug resistance and enriches cancer stem cells (CSCs) during cancer chemotherapy. Previous studies showed that GCS modulates the expression of p53 mutants and oncogenic gain-of-function (GOF) in heterozygous knock-in cell models...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucosyltransferases

Share to Homozygote

Share to Neoplastic Stem Cells

Share to Oxaliplatin

Share to Paclitaxel

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41977417
DOI: 10.3390/ijms27073237
PMCID: PMC13073438

Genes

UGCG
METTL3
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants.PMID 41977417Read ↗

Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.Semantic proximity Read ↗

CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancerSemantic proximity Read ↗

Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactionsSemantic proximity Read ↗

Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signalingSemantic proximity Read ↗

Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer.Semantic proximity Read ↗

Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors.Semantic proximity Read ↗

Rewiring glucose metabolism improves 5-FU efficacy in glycolytic p53-deficient colorectal tumorsSemantic proximity Read ↗

Transcriptome analysis of polyploid giant cancer cells and their progeny reveals a functional role for p21 in polyploidization and depolyploidizationSemantic proximity Read ↗

Targeting glypican‐4 overcomes 5‐FU resistance and attenuates stem cell–like properties via suppression of Wnt/β‐catenin pathway in pancreatic cancer cellsSemantic proximity Read ↗

Chemosensitivity of human colon cancer cells is influenced by a p53-dependent enhancement of ceramide synthase 5 and induction of autophagySemantic proximity Read ↗

Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling.Semantic proximity Read ↗

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.